For Investors

EuMentis Therapeutics is a clinical stage biopharmaceutical company focused on the development and commercialization of novel circuit-selective drugs to treat neurodevelopmental and other central nervous system conditions.  EuMentis is conducting a phase 2 study of EM-113 an uncompetitive fast-off antagonist of the NMDA receptor.  A randomized, placebo-controlled clinical trial at a major academic institution found memantine is highly effective in a subpopulation of autism spectrum disorder patients with elevated glutamate in a region of the brain called the anterior cingulate cortex, which plays a key role in social information processing.  EuMentis has an exclusive license to use this biomarker to identify and treat ASD patients with any NMDA antagonist.

EuMentis is also planning to initiate a phase 2 trial in Tourette syndrome with EM-221, a novel PDE10A antagonist, in Q1 2025.  PDE10A inhibitors specifically modulate the striatum in the brain, and a substantial body of  research points to dysregulation of striatal dopamine pathways as an underlying cause of the involuntary tics and vocalizations experienced by persons with Tourette syndrome.  EM-221 is expected to be both efficacious and safer than antipsychotics, which have considerable safety and tolerability problems but are the only approved treatments to date.

We are always looking to capitalize on our team’s talent and experience by partnering with like-mined companies or investors.

For more information, please contact Mike Moyer (mmoyer@lifesciadvisors.com)